HKI-272 for HER2-Positive Breast Cancer and Brain Metastases
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: HKI-272|PROCEDURE: Surgical Resection|DRUG: Capecitabine|DRUG: HKI-272|DRUG: Ado-Trastuzumab Emtansine
Sponsor: Dana-Farber Cancer Institute
Collaborators: Translational Breast Cancer Research Consortium|Puma Biotechnology, Inc.